{"organizations": [], "uuid": "3f813e141c2321f6fc8223923f4039c294134a3f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180228.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-asterias-provides-update-for-its-a/brief-asterias-provides-update-for-its-ast-opc1-phase-1-2aclinical-trial-idUSASB0C83O", "country": "US", "domain_rank": 408, "title": "BRIEF-Asterias Provides Update For Its AST-OPC1 Phase 1/2A Clinical Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.881, "site_type": "news", "published": "2018-03-01T06:01:00.000+02:00", "replies_count": 0, "uuid": "3f813e141c2321f6fc8223923f4039c294134a3f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-asterias-provides-update-for-its-a/brief-asterias-provides-update-for-its-ast-opc1-phase-1-2aclinical-trial-idUSASB0C83O", "ord_in_thread": 0, "title": "BRIEF-Asterias Provides Update For Its AST-OPC1 Phase 1/2A Clinical Trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "asterias biotherapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 28 (Reuters) - Asterias Biotherapeutics Inc:\n* ASTERIAS PROVIDES UPDATE FOR ITS AST-OPC1 PHASE 1/2A CLINICAL TRIAL IN SEVERE SPINAL CORD INJURY\n* ASTERIAS BIOTHERAPEUTICS INC - ‍RESULTS TO DATE SHOW AST-OPC1‘S FAVORABLE SAFETY PROFILE, POTENTIAL FOR CELL ENGRAFTMENT AND IMPROVED MOTOR FUNCTION​\n* ASTERIAS BIOTHERAPEUTICS INC - ‍MULTIPLE ADDITIONAL DATA READOUTS FROM SCISTAR STUDY EXPECTED IN 2018 INTO Q1 OF 2019​\n* ASTERIAS BIOTHERAPEUTICS INC - ‍THERE HAVE BEEN NO SERIOUS, UNEXPECTED, ADVERSE EVENTS RELATED TO AST-OPC1, INJECTION PROCEDURE​\n* ASTERIAS BIOTHERAPEUTICS INC - ‍TO DATE, THERE HAVE BEEN NO SERIOUS ADVERSE EVENTS RELATED TO AST-OPC1 CELLS​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-01T06:01:00.000+02:00", "crawled": "2018-03-01T20:58:21.000+02:00", "highlightTitle": ""}